42Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
New Zealand
Neuroscience Intelligence
New Zealand neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #41 of 50 · Data maturity A · Research score 29.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
11Recruiting trials
38Publications
24Institutions
Executive interpretation
New Zealand ranks #41 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC105 recruiting
Pfizer30 recruiting
Celgene20 recruiting
Boehringer Ingelheim20 recruiting
Forest Laboratories20 recruiting
Chelsea Therapeutics10 recruiting
BRC Operations Pty. Ltd.10 recruiting
Friedreich's Ataxia Research Alliance11 recruiting
Boston Children's Hospital10 recruiting
Cochlear10 recruiting
Disease activity
Parkinsons15trials
Other Neurology4trials
Stroke4trials
Huntingtons2trials
Multiple Sclerosis2trials
Alzheimers2trials
Autism2trials
Epilepsy2trials
Schizophrenia2trials
Neurodevelopmental Other1trials
Research institutions
Starship Children's HealthOpenAlexlinked institution
Capital and Coast District Health BoardOpenAlexlinked institution
Auckland District Health BoardOpenAlexlinked institution
University of OtagoOpenAlexlinked institution
Palmerston North HospitalOpenAlexlinked institution
Middlemore HospitalOpenAlexlinked institution
Department of ConservationOpenAlexlinked institution
Auckland City HospitalOpenAlexlinked institution
Brain Research New ZealandOpenAlexlinked institution
Nelson Marlborough Institute of TechnologyOpenAlexlinked institution
Clinical evidence trail
NCT07777549A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)NOT_YET_RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06961006A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)RECRUITING
NCT06504394A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)ACTIVE_NOT_RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)ACTIVE_NOT_RECRUITING
NCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's DiseaseRECRUITING
Research evidence trail
PUBMEDCerebrospinal fluid and dural accumulation of α-synuclein impairs CNS clearance in Parkinson's disease.2026-11-02
PUBMEDCortical Cholinergic Pathway Degeneration Reflects Cognitive Impairment and Dementia in Parkinson's Disease.2026-10-19
PUBMEDLong-term outcomes associated with adolescent ADHD symptomatology: birth cohort study.2026-10-01
PUBMEDEarly Arterial Oxygen Tension Thresholds for Mechanically Ventilated Patients with Non-traumatic Acute Brain Injury: A Bayesian Analysis of Three Large Neurocritical Care Datasets.2026-09-28
PUBMEDFactors associated with variability in recovery after mild traumatic brain injury among adults referred to outpatient concussion clinics.2026-09-24
PUBMEDPrimary care clinicians' perspectives on migraine management in Aotearoa New Zealand: a qualitative study.2026-09-24
PUBMEDDabigatran use and cerebrovascular event risk across body mass index in atrial fibrillation: a real-world nested case-control study.2026-09-07
PUBMEDDevelopment-related gene expression disruption in the human midcingulate cortex in Huntington's disease.2026-08-01
PUBMEDExploration of the genetic neuroinflammatory environment in the human midcingulate cortex in Huntington's disease.2026-06-04
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.